Ncardia originated from the biotechnology company Pluriomics, which was founded in 2001, and has developed into a globally active research and development company specializing in applied stem cell technologies. With operations in Belgium, the Netherlands and the United States, the company supports scientists and pharmaceutical developers in the discovery and development of therapies based on human induced pluripotent stem cells (hiPSCs). Its activities focus on providing advanced cellular models and research platforms for drug discovery, disease modeling and preclinical testing. A particular emphasis is placed on studies evaluating the cardiovascular and neurological safety and efficacy of new drug candidates. Through its scientific expertise and innovative technologies, Ncardia contributes to accelerating biomedical research and the development of next-generation therapies.